Oruka Therapeutics (ORKA) Free Cash Flow (2010 - 2026)

Oruka Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$23.7 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 13.26% year-over-year to -$23.7 million in Q1 2026; TTM through Mar 2026 was -$91.2 million, a 16.09% decrease from a year earlier, with the FY2025 full-year figure at -$88.4 million, down 52.76% from the prior year.
• Free Cash Flow fell to -$23.7 million in Q1 2026 per ORKA's latest filing, from -$22.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$168000.0 in Q1 2024 and bottomed at -$27.8 million in Q3 2024.
• The 5-year median for Free Cash Flow is -$4.3 million (2022), against an average of -$10.9 million.
• Across the five-year window, Free Cash Flow soared 89.47% in 2024 and sank 12329.76% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$1.5 million in 2022, then advanced by 29.22% to -$1.1 million in 2023, then plunged by 1682.01% to -$18.8 million in 2024, then retreated by 20.49% to -$22.7 million in 2025, then decreased by 4.31% to -$23.7 million in 2026.
• Per Business Quant, the three latest ORKA Free Cash Flow figures stand at -$23.7 million (Q1 2026), -$22.7 million (Q4 2025), and -$21.7 million (Q3 2025).